VOYXACT

all catalysts(0)

nothing on the calendar yet

News(10)

• Vertex opens up larger kidney disease opportunity with mid-stage readout
  While Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…
  biospace · 26d ago
• Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
  Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month…
  biospace · 2mo ago
• Boulevard starts up with $65M to pursue targeted autoimmune drugs
  Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
  biopharma_dive · 2mo ago
• Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
  ✅ Otsuka’s confirmatory kidney disease data: The drugmaker said Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study in patients with IgA nephropathy (IgAN). The treatment increased…
  endpoints · 2mo ago
• Vertex unfazed by competitive IgAN space as FDA verdict looms
  Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…
  biospace · 2mo ago
• Vera Therapeutics wins FDA nod for closely watched kidney disease drug
  The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year.
  biopharma_dive · 3mo ago
• Otsuka reports long-term kidney data key to Voyxact's bid for full approval
  Otsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabiliz…
  endpoints · 3mo ago
• BridgeBio gets funding for drug launch; United buys into cell therapy
  Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
  biopharma_dive · 3mo ago
• Otsuka touts new IgAN evidence as it seeks full approval for Voyxact
  Otsuka Pharmaceutical reported new evidence on Thursday that it thinks will help support a full approval for its monoclonal antibody Voyxact in a chronic autoimmune disease that affects the kidneys…
  endpoints · 4mo ago
• STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
  Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
  stat · 4mo ago